Gene modifiers of lung disease

Current Opinion in Pulmonary Medicine

Volumn 12, Issue 6, 2006, Pages 416-421

  Knowles, Michael R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Gene modifier; Mendelian; Phenotype; Single nucleotide polymorphism

Indexed keywords

MANNOSE BINDING LECTIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CHROMOSOME; CYSTIC FIBROSIS; DISEASE SEVERITY; DNA MODIFICATION; FORCED EXPIRATORY VOLUME; GENE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENETICS; GENOME; HUMAN; LUNG DISEASE; LUNG FUNCTION; MONOGENIC DISORDER; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPIROMETRY;

CYSTIC FIBROSIS; GENES, RECESSIVE; GENETIC HETEROGENEITY; GENOME, HUMAN; HUMANS; LUNG DISEASES; SEVERITY OF ILLNESS INDEX; VARIATION (GENETICS);

EID: 33750364841     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000245707.59138.40     Document Type: Review

References (38)

1. Welsh MJ, Ramsey BW, Accurso FJ, et al. Cystic Fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and molecular bases of inherited disease, 8. New York: McGraw-Hill; 2001. pp. 5121-5188.
2. 508). N Engl J Med 1990; 323:1517-1522.
3. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73:1251-1254.
4. Knowles MR, Durie PR. What is cystic fibrosis? N Engl J Med 2002; 347:439-442.
5. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326:1187-1191.
6. Mekus F, Ballmann M, Bronsveld I, et al. Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res 2000; 3:277-293.
7. Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet 2005; 6:237-260. A comprehensive review of all cystic fibrosis modifier studies through early 2005, with a discussion that provides a pertinent overview of specific genetic variants.
8. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet 2001; 2:165-174.
9. Noone PG, Knowles MR. 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res 2001; 2:328-332.
10. Van Heyningen V, Yeyati PL. Mechanisms of non-Mendelian inheritance in genetic disease. Hum Mol Genet 2004; 13:R225-R233.
11. Newton-Cheh C, Hirschhorn JN. Genetic association studies of complex traits: design and analysis issues. Mutat Res 2005; 573:54-69.
12. Laird NM, Lange C. Family-based designs in the age of large-scale geneassociation studies. Nat Rev Genet 2006; 7:385-394.
13. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002; 109:571-577.
14. Drumm ML, Konstan MW, Schluchter MD, et al. Gene modifiers of lung disease in cystic fibrosis. N Engl J Med 2005; 353:1443-1453. The first study of multiple candidate modifiers in a large population (>800) of ΔF508 homozygotes. The study defined variation in TGFβ1 as an adverse modifier of cystic fibrosis lung disease, which was replicated in an additional 498 cystic fibrosis patients.
15. Corey M, Edwards L, Levison H, et al. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997; 131:809-814.
16. Schluchter MD, Konstan MW, Davis PB. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002; 21:1271-1287.
17. Garred P, Pressler T, Madsen HO, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999; 104:431-437.
18. Davies JC, Turner MW, Klein N, et al. Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J 2004; 24:798-804.
19. Carlsson M, Sjoeholm AG, Eriksson L, et al. Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship. Clin Exp Immunol 2005; 139:306-313.
20. Yarden J, Radojkovic D, De Boeck K, et al. Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype. J Med Genet 2004; 41:629-633.
21. Kulich M, Rosenfeld M, Campbell J, et al. Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172:885-891. This paper describes a new approach to estimating pulmonary status in cystic fibrosis, by comparing spirometric parameters to age- and gender-matched cystic fibrosis patients, rather than a normal population.
22. ••].
23. Frangolias DD, Ruan J, Wilcox PJ, et al. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol 2003; 29:390-396.
24. ••] that contributed to the power of the analysis and replication of TGFβ1 variants as modifiers of cystic fibrosis lung disease.
25. Blackman SM, Deering-Brose R, McWilliams R, et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology (in press).
26. Vanscoy LL, Lai T, Bowers A, et al. Modifier genes may contribute substantially to variation in cystic fibrosis (CF) lung disease estimated by CF-specific % for FEV1. Proc Am Thorac Soc 2006; 3:A408.
27. Dorfman R, Sandford A, Corey M, et al. Canadian CF modifier gene project: the current status. Pediatr Pulmonol 2005; 28 (suppl):248.
28. Choi EH, Ehrmantraut M, Foster CB, et al. Association of common haplotypes of surfactant protein A1 and A2 (SFTPA1 and SFTPA2) genes with severity of lung disease in cystic fibrosis. Pediatr Pulmonol 2006; 41:255-262.
29. Davies JC, Griesenbach U, Alton E. Modifier genes in cystic fibrosis. Pediatr Pulmonol 2005; 39:383-391.
30. Yarden J, Radojkovic D, De Boeck K, et al. Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 2005; 60:320-325.
31. McKone EF, Shao J, Frangolias DD, et al. Variants in the glutamate-cysteineligase gene are associated with cystic fibrosis lung disease. Am J Respir Crit Care Med 2006; 174:415-419.
32. Courtney JM, Plant BJ, Morgan K, et al. Association of improved pulmonary phenotype in Irish cystic fibrosis patients with a 3′ enhancer polymorphism in alpha-1-antitrypsin. Pediatr Pulmonol 2006; 41:584-591.
33. Vankeerberghen A, Scudiero O, De Boeck K, et al. Distribution of human beta-defensin polymorphisms in various control and cystic fibrosis populations. Genomics 2005; 85:574-581.
34. Stanke F, Becker T, Cuppens H, et al. The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Hum Genet 2006; 119:331-343.
35. Wang WY, Barratt BJ, Clayton DG, et al. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005; 6:109-118.
36. Thomas DC, Haile RW, Duggan D. Recent developments in genomewide association scans: a workshop summary and review. Am J Hum Genet 2005; 77:337-345. An excellent and authoritative overview of the evolving status of whole-genome scans.
37. Silverman ES, Palmer LJ, Subramaniam V, et al. Transforming growth factorbeta1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med 2004; 169:214-219.
38. Celedon JC, Lange C, Raby BA, et al. The transforming growth factor-{beta}1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 2004; 13:1649-1656.